Recent developments in pharmacotherapy for the acutely psychotic patient.
Daniel
David G
DG
Bioniche Development, Inc, McLean, VA 22106, USA. DrDaniel@bionichegroup.com
D018726:Anti-Dyskinesia Agents / Q000008:administration & dosage; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001569:Benzodiazepines; D006220:Haloperidol / Q000008:administration & dosage; D006801:Humans; D007273:Injections, Intramuscular; D000077152:Olanzapine; D010879:Piperazines / Q000008:administration & dosage; D010890:Pirenzepine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011595:Psychomotor Agitation / Q000188:drug therapy; D011618:Psychotic Disorders / Q000188:drug therapy*; D013844:Thiazoles / Q000008:administration & dosage
D018726:Anti-Dyskinesia Agents; D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; D001569:Benzodiazepines; D010890:Pirenzepine; C092292:ziprasidone; D006220:Haloperidol; D000077152:Olanzapine